Phaseline

Targets › TRBC1

TRBC1 (T cell receptor beta constant 1): drug programs, companies and trials

3 programs from 3 companies in 3 trials: 2 Phase 2, 1 Phase 1; Oncology; next expected readout Jan 2028.

Constant region of T cell receptor (TR) beta chain. Alpha-beta T cell receptors are antigen specific receptors which are essential to the immune response and are present on the cell surface of T lymphocytes. (UniProt, P01850)

Open in Phaseline: the race on TRBC1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Copenhagen University Hospital, RigshospitaletiDLI (innate donor lymphocyte infusion)
TCRαβ/CD19 depleted donor lymphocyte infusion enriched for NK cells (>10e7 cells/kg) and T
TRBC1, TRBC2, CD19Phase 2AML/MDSJan 2028
Peking University People's HospitalReduced ATG plus mini PTCy
Combination of anti-thymocyte globulin (ATG) and post-transplantation cyclophosphamide (PT
TRAC, TRBC1, TRBC2Phase 2Myelodysplastic Syndrome–
Second Affiliated Hospital, Zhejiang University, School of MedicineAnti-TRBC1 CAR-NK cells
Umbilical cord blood-derived NK cells expressing anti-TRBC1/2 CAR
TRBC1, TRBC2Phase 1Refractory/Recurrent Peripheral T-cell LymphomaJan 2029

Conditions

Refractory/Recurrent Peripheral T-cell Lymphoma (1) Myelodysplastic Syndrome (1) AML/MDS (1)

Modalities

other (1), small molecule (1)

Companies

Second Affiliated Hospital, Zhejiang University, School of Medicine (1) Peking University People's Hospital (1) Copenhagen University Hospital, Rigshospitalet (1)

Related targets

TRBC2 (3) TRAC (1) CD19 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.